Pruritus and quality of life in moderate-to-severe plaque psoriasis: Post hoc explorative analysis from the PRISTINE study

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 6, 2015, Pages 1114-1120

  Mrowietz, U ^a   Chouela, E N ^b   Mallbris, L ^c   Stefanidis, D ^c   Marino, V ^c   Pedersen, R ^c   Boggs, R L ^c  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b HOSPITAL DURAND   (Argentina)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; EUROQOL 5 DIMENSION; FEMALE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL OUTCOMES STUDY SLEEP INDEX II; POST HOC ANALYSIS; PRIORITY JOURNAL; PRURITUS; PSORIASIS; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER ASSESSMENT; TREATMENT OUTCOME; VISUAL ANALOG SCALE; ANXIETY; COMPLICATION; DEPRESSION; MIDDLE AGED; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; ANXIETY; DEPRESSION; DOUBLE-BLIND METHOD; ETANERCEPT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PRURITUS; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 84929650397     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12761     Document Type: Article

References (32)

1. Yosipovitch G, Goon A, Wee J, Chan YH, Goh CL,. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 2000; 143: 969-973.
2. Amatya B, Wennersten G, Nordlind K,. Patients' perspective of pruritus in chronic plaque psoriasis: a questionnaire-based study. J Eur Acad Dermatol Venereol 2008; 22: 822-826.
3. Reich A, Hrehorow E, Szepietowski JC,. Pruritus is an important factor negatively influencing the well-being of psoriatic patients. Acta Derm Venereol 2010; 90: 257-263.
4. Chang SE, Han SS, Jung HJ, Choi JH,. Neuropeptides and their receptors in psoriatic skin in relation to pruritus. Br J Dermatol 2007; 156: 1272-1277.
5. Sampogna F, Gisondi P, Melchi CF, Amerio P, Girolomoni G, Abeni D,. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol 2004; 151: 594-599.
6. Gottlieb A, Feng J, Harrison DJ, Globe D,. Validation and response to treatment of a pruritus self-assessment tool in patients with moderate to severe psoriasis. J Am Acad Dermatol 2010; 63: 580-586.
7. Dauden E, Griffiths CE, Ortonne JP, et al,. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol 2009; 23: 1374-1382.
8. Krueger GG, Langley RG, Finlay AY, et al,. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 2005; 153: 1192-1199.
9. Prinz JC, Fitzgerald O, Boggs RI, et al,. Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial. J Eur Acad Dermatol Venereol 2011; 25: 559-564.
10. Strohal R, Puig L, Chouela E, et al,. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). J Dermatolog Treat 2012; 24: 169-178.
11. Badia X, Mascaro JM, Lozano R,. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. The Cavide Research Group. Brit. J Dermatol 1999; 141: 698-702.
12. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
13. Lewis V, Finlay AY,. 10 years experience of the dermatology life quality index (DLQI). J Investig Dermatol Symp Proc 2004; 9: 169-180.
14. Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA,. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes 2003; 1: 53.
15. Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA,. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006; 4: 71.
16. Finlay AY,. Current severe psoriasis and the rule of tens. Br J Dermatol 2005; 152: 861-867.
17. Brooks R, Rabin R, de Charro F, eds. The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective: Evidence from the EuroQol BIOMED Research Programme, 1st edn. Springer, New York, 2003.
18. EuroQOL Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
19. Kind P,. The EuroQol instrument: an index of health-related quality of life., Spilker B,. Philadelphia: Lippincott-Raven, 1996: 191-201.
20. Dolan P,. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095-1108.
21. Kind P, Hardman G, Marcran S, eds. UK Population Norms for EQ-5D. Centre for Health Economics, University of York, York, 1999.
22. Snaith RP,. The hospital anxiety and depression scale. Health Qual Life Outcomes 2003; 1: 29.
23. Snaith RP, Zigmond AS,. The hospital anxiety and depression scale with the irritability-anxiety-depression scale and the leeds situational anxiety scale manual. NFER Nelson Publishing Company, Ltd, London, 1994.
24. Webster K, Cella D, Yost K,. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes 2003; 1: 79.
25. Cella D, Lai JS, Chang CH, Peterman A, Slavin M,. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002; 94: 528-538.
26. Hays RD, Martin SA, Sesti AM, Spritzer KL,. Psychometric properties of the Medical Outcomes Study Sleep measure. Sleep Med 2005; 6: 41-44.
27. Rejas J, Ribera MV, Ruiz M, Masrramon X,. Psychometric properties of the MOS (Medical Outcomes Study) Sleep Scale in patients with neuropathic pain. Eur J Pain 2007; 11: 329-340.
28. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY,. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005; 125: 659-664.
29. Amatya B, Nordlind K,. Focus groups in Swedish psoriatic patients with pruritus. J Dermatol 2008; 35: 1-5.
30. Pearce DJ, Spencer L, Hu J, Balkrishnan R, Fleischer AB Jr, Feldman SR,. Class I topical corticosteroid use by psoriasis patients in an academic practice. J Dermatolog Treat 2004; 15: 235-238.
31. Revicki DA, Willian MK, Menter A, et al,. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat 2007; 18: 341-350.
32. Revicki D, Willian MK, Saurat JH, et al,. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008; 158: 549-557.